Ignite Creation Date:
2025-12-26 @ 11:07 AM
Ignite Modification Date:
2026-01-13 @ 6:38 PM
Study NCT ID:
NCT06548412
Status:
RECRUITING
Last Update Posted:
2025-07-25
First Post:
2024-08-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-01-22
Start Date Type:
ACTUAL
Primary Completion Date:
2027-05-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2029-05-01
Completion Date Type:
ESTIMATED
First Submit Date:
2024-08-08
First Submit QC Date:
None
Study First Post Date:
2024-08-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-24
Last Update Post Date:
2025-07-25
Last Update Post Date Type:
ACTUAL